Abstract-Current research suggests that estrogen may have primary effects on the artery wall. To investigate the mechanisms of female sex hormone actions in the artery wall, we used an isolated, perfused, rat carotid artery model to examine the effects of estradiol on the rates of accumulation of normal (N-LDL) and minimally modified (MM-LDL) low density lipoprotein in ovariectomized rats. N-LDL, MM-LDL, and oxidized LDL (OX-LDL) were fluorescently labeled and perfused into individual arteries. The rate of LDL accumulation was measured by quantitative fluorescence microscopy before and after treatment with estradiol (1 nmol/L, 272 pg/mL). Estradiol had no effect on the rate of Key Words: artery Ⅲ arteriosclerosis Ⅲ LDL Ⅲ estrogen Ⅲ oxidized LDL Ⅲ endothelium Ⅲ permeability A cardinal characteristic of the development of atherosclerosis is the accumulation of LDL within the arterial wall. 1-3 Sites of relative increase in LDL permeability have been identified in normal arteries 4 and can be induced by injury to the endothelium. 5-9 Alternatively, others have reported increased binding and decreased efflux of LDL from the vascular wall, even under conditions where LDL influx was not affected. 10, 11 Therefore, LDL accumulation in the artery wall potentially occurs by several mechanisms, perhaps depending on the stage of atheroma formation.
A cardinal characteristic of the development of atherosclerosis is the accumulation of LDL within the arterial wall. [1] [2] [3] Sites of relative increase in LDL permeability have been identified in normal arteries 4 and can be induced by injury to the endothelium. [5] [6] [7] [8] [9] Alternatively, others have reported increased binding and decreased efflux of LDL from the vascular wall, even under conditions where LDL influx was not affected. 10, 11 Therefore, LDL accumulation in the artery wall potentially occurs by several mechanisms, perhaps depending on the stage of atheroma formation.
A large body of evidence indicates that modification of LDL in the artery wall promotes atherosclerosis. 12 Recent studies demonstrate evidence of modification of LDL in the blood. [13] [14] [15] [16] [17] Furthermore, a previous study showed increased accumulation and degradation of oxidized LDL (OX-LDL) in the artery wall in vivo. 18 These studies suggest that the reason there is increased accumulation and degradation of OX-LDL is because arterial permeability to undegraded, OX-LDL is greater than arterial permeability to native LDL (N-LDL). However, the precise mechanism(s) by which modified LDL (MM-LDL) affects LDL flux in the artery wall, such as increases in permeability to LDL, remains incompletely understood.
Modification of LDL (eg, oxidation), either in the circulation or the artery wall, could promote atherosclerosis by increasing LDL accumulation in the artery. Also, alteration of constituents of the artery wall, such as proteoglycans, could influence LDL binding to the artery wall. Furthermore, oxidant-mediated injury of endothelial cell membranes could compromise the endothelial layer barrier to macromolecules in arteries. 5 To counteract oxidant stress effects on LDL and/or the artery wall, a number of potential antioxidants have been examined. In particular, some estrogens (eg, 17␤-estradiol) are known to reduce LDL accumulation in the artery wall 19, 20 and to be potent antioxidants. [21] [22] [23] In addition, estrogens may protect endothelial cells from oxidative damage. 21, 22 This action would be expected to prevent increased LDL permeation into the artery wall. Furthermore, estradiol has been shown to inhibit LDL oxidation in vivo at supraphysiological 24 and physiological 25 concentrations. These data suggest that some estrogens may beneficially affect LDL or the artery wall by their antioxidant effects.
To examine the interactions of MM-LDL and estradiol in the artery wall, we developed a system to perfuse individual arteries with N-LDL, MM-LDL, and OX-LDL and to test the actions of estradiol on LDL flux in the artery wall. Our results show greater accumulation of MM-LDL than N-LDL. Furthermore, estradiol decreased accumulation of both MM-LDL and OX-LDL and prevented compromise of endothelial layer integrity induced by MM-LDL.
Methods

Chemicals and Materials
Krebs-Henseleit buffer consisted of (in mmol/L) NaCl 116, KCl 
Experimental Animals
Female Crl:CD (SD) BR rats (100 to 150 g) obtained from Charles River Breeding Laboratories (Boston, Ma) were used in all experiments. Animals were individually housed in plastic cages with a stainless steel cover. They were given tap water and Purina Laboratory Rodent Chow ad libitum. The animal housing facility and experimental protocol was approved by the Animal Use Committee at the University of California at Davis.
Ovariectomy Surgery
Rats were anesthetized with an intraperitoneal injection of ketamine (80 mg/kg) and xylazine (10 mg/kg). A 0.5-to 1.0-cm longitudinal incision was made in the midline dorsal area of the back from the second to the fifth lumbar vertebrae. 26 A small peritoneal incision was made and the ovaries were located. Once the ovaries were tied off at the tip of the uterus, they were removed. Vexaband tissue glue and sutures (absorbable 3-0, Dexon II) were used to close the incisions. Animals were given an intramuscular injection of an antibiotic (enrofloxicine, 10 mg/kg) and placed on a heating pad until they recovered.
Isolation and Modification of LDLs
Human blood was collected in citrate from healthy male donors at the San Diego Blood Bank. LDL was isolated by density gradient ultracentrifugation and was stored in Dulbecco's modified Eagle's medium with 0.3 mmol/L EDTA. 27 Immediately before oxidation, antioxidants were removed from LDL by overnight dialysis against saline. Lipoproteins were modified by incubating LDL (2.5 mg protein per mL) with 5 mol/L copper acetate (Cu 2ϩ ), and the extent of modification was measured by thiobarbiturate-reactive substances (TBARS). 27, 28 MM-LDL (TBARSϭ2.4 to 6.8 nmol malondialdehyde equivalent s per mg protein) was obtained by incubating human N-LDL with Cu 2ϩ for 1 hour, and the OX-LDL (TBARSϭ7.5 to 32.7 nmol/mg) was obtained by incubating N-LDL with Cu 2ϩ for 18 hours. In comparison, N-LDL had TBARS values of 0.00 to 1.71 nmol malondialdehyde equivalents per mg protein. N-LDL, MM-LDL, and OX-LDL used in a given protocol were from the same male donor. Each of the protocols was conducted with LDL from a different donor.
Fluorescent Labeling of LDL and Dextran
N-LDL, MM-LDL, and OX-LDL were labeled with the fluorescent hydrocarbon probe 1,1-dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine (DiI) as described by Pitas et al. 29 Dil exchanges with lipoprotein phospholipid and does not transfer the fluorescent probe because the 2 octadecyl moieties make the compound hydrophobic. The spectral properties of Dil are the following: excitation maximum at 540 nm and emission maximum at 556 nm. Dextran (64 000 molecular weight) was obtained from Sigma labeled with TRITC. The spectral properties of TRITC are excitation maximum at 554 nm and emission maximum at 573 nm.
Experimental Protocol
Four to 6 weeks after ovariectomy, the arterial perfusion experiments were performed. 6, 30 Rats were anesthetized by intraperitoneal injection of sodium pentobarbital (35 mg/kg). After the rat was anesthetized, a midline incision was made in the neck, and both carotid arteries were dissected free from connective tissue. An incision was made in the proximal segment of the artery, and a cannula (23-gauge tubing adapter connected to polyethylene-50 tubing) was inserted into the carotid artery. The cannula was tied in place (silk 6-0). Another incision was made in the distal portion of the artery proximal to the bifurcation of the internal and external carotid arteries. Another cannula (identical to the proximal cannula) was inserted into the distal carotid artery and tied in place. The artery was removed from the animal and placed into a fluid-filled, clear Plexiglas chamber on the microscope stage (perfusion chamber). Throughout the surgery, the artery was superfused with KrebsHenseleit solution gassed with 95% O 2 and 5% CO 2 . The KrebsHenseleit solution traveled from a reservoir through a heating coil to the superfusate chamber and was maintained at 37°C throughout the experiment.
To reduce the number of animals needed for these experiments, both carotid arteries were isolated and used for perfusion. A single experiment was performed on each artery, and protocols were performed in sequence. For example, in protocol 1 the rates of LDL accumulation for N-LDL, MM-LDL, and OX-LDL were performed in 3 sequential arteries (2 carotid arteries from 1 animal and 1 carotid artery from the second animal). The sequence began again with the second carotid artery from the second animal.
The artery was perfused with Krebs-Henseleit solution containing 1% BSA (perfusate solution), also gassed with 95% O 2 and 5% CO 2 . The perfusate solution entered the artery through the proximal cannula and exited the artery through the distal cannula. By using 3-way stopcocks and 2 parallel sets of tubing, the artery was perfused with either the nonfluorescent solution or the fluorescent solution. The arteries were perfused antegradely by a peristaltic pump. A normal flow rate was maintained in the carotid artery (7 mL/min). Periodic measurements of pH and partial pressures of O 2 and CO 2 were obtained to maintain physiological conditions.
Experimental Apparatus
The experimental apparatus used to measure LDL flux consisted of an inverted Nikon microscope with objective (planϫ6.3; numerical aperture, 0.2) mounted on the microscope head. The fluorescence image was transmitted through a beam splitter to a Dage low-light television camera and a Nikon P101 photometer. The photometer used to measure changes in fluorescence intensity was connected to a chart recorder and computer. Output from the camera was input into the videocassette recorder and to a high-resolution monitor. Images of the labeled LDL flux were recorded on videotape and assessed later by image analysis. 31 
Measurement of LDL Accumulation and Lumen Volume
Several measurements were made during and after perfusion of each carotid artery with fluorescently labeled molecules. Initially, a baseline measurement of fluorescence intensity (If) was established while the artery was perfused with the nonfluorescent solution ( Figure 1 ). Then, the artery was perfused with the fluorescent solution, and a step increase in fluorescence intensity was observed. Fluorescence intensity rapidly increased to approach an asymptotic value (If 0 ). Simultaneously, LDL may become associated with the luminal surface of the artery or enter the artery wall. If the perfusate concentration of the fluorescently labeled molecules and perfusate flow remain constant, then If 0 determined at the asymptotic value estimated the lumen volume. 30 As the artery continued to be perfused with fluorescent solution, some of the labeled molecules became bound to the endothelium and/or crossed into the artery wall. After washout with the nonfluorescent solution, labeled molecules that remained on the luminal surface or in the artery wall were termed If accumulation. Therefore, molecule accumulation in the artery wall was determined photometrically (in millivolts) and was a measure of the number of fluorescent molecules that remained on the lumen surface or in the artery wall. 6 The rate of molecule accumulation is If accumulation divided by perfusion time. Using this approach, we were able to measure If accumulation multiple times ( Figure 2) . Furthermore, the effect of estradiol can be determined by adding estradiol to both the fluorescent and nonfluorescent solutions after control rates of If accumulation have been determined.
To relate fluorescence intensity (If) to lumen volume, we determined the fluorescence intensity of a given amount of LDL in the artery lumen. The volume of the artery was determined by ⅐ radius 2 ⅐ length. Thus, fluorescence intensity in the lumen can be related to units of volume to indirectly measure artery lumen volume.
Accumulation (If) in millivolts was converted to nanograms of cholesterol per square centimeter per hour as we have described previously. 32 The rates of DiI-N-LDL, DiI-MM-LDL, and DiI-OX-LDL efflux were determined, as we have described previously. 6 In summary, the rate of decay of fluorescence intensity was determined after the fluorescently labeled LDL solution was washed from the vessel lumen. The decay in fluorescence then represents the efflux of LDL back into the artery lumen.
Plasma Estradiol Measurements
After isolation and cannulation of the carotid artery, blood was collected from each animal via the right atrium by using a 22-gauge needle and heparinized syringe. Blood was transferred to evacuated containers and centrifuged (2800 rpm for 10 minutes). Plasma was immediately separated from red blood cells and kept on ice. The samples were sent to the Endocrinology Laboratory of the School of Veterinary Medicine at the University of California at Davis for analysis of estradiol concentration by using a charcoal-based, tritium-labeled radioimmunoassay. 33 The mean plasma estradiol level 4 to 6 weeks after ovariectomy was 11.2Ϯ1.4 pg/mL.
Statistical Analysis
Multiple measurements of the rate of LDL accumulation and lumen volume were made from each artery for each treatment. To give each artery and each treatment equal weight, the mean of all measurements of the rates of LDL accumulation and lumen volume were determined for each treatment in each artery. Group data of each treatment are presented as the meanϮSEM. Group data were analyzed by repeated-measures ANOVA (Sigma Stat statistical hardware, Jandel Corp). Significant effects were assessed with the Student-Newman-Keuls multiple-comparison test. A probability level of PՅ0.05 was considered statistically significant.
Results
Accumulation of N-LDL, MM-LDL, and OX-LDL in the Artery Wall: Protocol 1
N-LDL, MM-LDL, and OX-LDL were labeled with DiI. Individual arteries were perfused with DiI-N-LDL (4 arteries), DiI-MM-LDL (4 arteries), or DiI-OX-LDL (4 arteries). The concentration of all fluorescently labeled LDL solutions was 0.042 mg/mL protein and 0.083 mg/mL cholesterol. In each artery, a baseline level of fluorescence intensity was determined by perfusing the artery with the nonfluorescent buffer solution (Figure 1) . Then, fluorescently labeled LDL was perfused for 10 minutes, followed by a 10-minute perfusion with nonfluorescent perfusate. The rate of LDL accumulation was determined after each 10-minute perfusion with fluorescently labeled LDL. Each artery had the rate of LDL accumulation determined 5 times (Figure 2 ). There was a significant increase in the rate of LDL accumulation during perfusion with MM-LDL and OX-LDL (175Ϯ32 and 178Ϯ5 ng cholesterol per cm 2 LDL, nϭ10 arteries; or OX-LDL, nϭ10 arteries) in the same concentrations as described above. Two arteries (N-LDL) developed leaks and were therefore technically unacceptable. In each artery, the rate of N-LDL, MM-LDL, or OX-LDL accumulation was determined. Then, while the nonfluorescent Krebs-Henseleit solution was being perfused, estradiol (1 nmol/L, 272 pg/mL) was added to both the nonfluorescent and fluorescent perfusion solutions ( Figure 5 ). Estradiol was solubilized in ethanol and diluted in Krebs-Henseleit buffer to its final concentration (0.000020% ethanol by volume). This concentration of estradiol has been shown not to affect the rate of LDL accumulation in the artery wall in short-term studies. 32 After estradiol was added to both the nonfluorescent and the fluorescently labeled LDL solutions, the artery was perfused for 10 minutes with the nonfluorescent solution. Then, the artery was perfused with the fluorescently labeled LDL solution for 10 minutes. Therefore, each artery was treated with estradiol for 20 minutes before the first measurements of the rates of accumulation of N-LDL, MM-LDL, or OX-LDL were made. As in the previous protocol, the rates of OX-LDL and MM-LDL accumulation were significantly greater than that of N-LDL accumulation. Furthermore, the rate of MM-LDL accumulation tended to be greater than that of OX-LDL accumulation. The rate of N-LDL accumulation (45Ϯ12 ng per cm 2 per h) was not changed after estradiol was added (48Ϯ15 ng per cm 2 per h; Figure 6 ). There was, however, a significant decrease in MM-LDL accumulation after the addition of estradiol to the perfusate (240Ϯ48 versus 160Ϯ48 ng per cm 2 
Effects of MM-LDL on Endothelial Layer Permeability: Protocol 3
To determine the effect of MM-LDL on endothelial layer permeability, we perfused the arteries with nonfluorescently labeled MM-LDL at a concentration range of 10 to 350 g/mL protein. Endothelial layer permeability after perfusion with MM-LDL was determined by measurement of accumulation of a nonlipid, water-soluble reference molecule (dextran, 64 000 molecular weight, at 75 g/mL and labeled with TRITC). Significant increases in the rates of dextran accumulation were first detected after perfusion with 100 g/mL MM-LDL (319Ϯ96 versus 510Ϯ191 ng per cm 2 per h; nϭ6 arteries; PϽ0.05). As in an in vivo control, we conducted a whole-animal perfusion and showed that MM-LDL did, in fact, accumulate in the carotid artery (Figure 7) .
To compare the effect of MM-LDL on endothelial layer permeability with other lipoproteins, we perfused arteries with nonfluorescently labeled HDL (0.2 mg/mL protein, 0.16 mg/mL cholesterol). No increase in the rate of dextran accumulation was noted after the artery wall was perfused with HDL (447 versus 383 ng cholesterol per cm 2 per h; nϭ2 arteries).
Impact of Estradiol on MM-LDL-Mediated Dextran Accumulation: Protocol 4
Next, we determined the effect of treatment of the artery with estradiol on the rate of dextran accumulation before and after perfusion with MM-LDL (100 g/mL). In each artery (nϭ6), the rate of dextran accumulation was determined during perfusion of the solution containing TRITC-labeled dextran (415Ϯ49 ng per cm 2 per h). Then, estradiol (272 pg/mL) was added to both the fluorescent and nonfluorescent solutions, and repeated measurements of the rate of dextran accumulation were made (479Ϯ85 ng per cm 2 per h). The rate of dextran accumulation after estradiol was added to the perfusate was not significantly different from control measurements. Then, MM-LDL (100 g/mL) was added to the nonfluorescent solution, and repeated measurements of the rate of dextran accumulation after MM-LDL exposure were made in the presence of estradiol (415Ϯ160 ng per cm 2 per h). Treatment of the artery with estradiol prevented the expected increase in the rate of dextran accumulation when perfused with MM-LDL. Thus, treatment with estradiol prevented MM-LDL-mediated compromise of the endothelial barrier function. Figure 5 . Summary of the sequence of perfusions of the nonfluorescent buffer solution and the buffer solutions containing the fluorescently labeled LDL. In protocol 2 and using the same format as described in protocol 1 (Figure 2) , the sequence of perfusions of the nonfluorescent buffer solution and the fluorescently labeled LDL solutions (DiI-N-LDL, DiI-MM-LDL, or DiI-OX-LDL) is depicted. Estradiol (272 pg/mL) was added to both nonfluorescent and fluorescent solutions after 3 perfusion of the fluorescent solution. For protocol 3, scheme of the sequence of perfusions is shown for the nonfluorescent buffer solution and the buffer solution containing TRITC-dextran (75 g/mL). MM-LDL (not fluorescently labeled) was added to the nonfluorescent solution after 3 perfusions of the solution containing TRITC-dextran. For protocol 4, sequence of perfusion is shown for the nonfluorescent buffer solution and the solution containing TRITC-dextran. Estradiol (272 pg/mL) was added after two 10-minute perfusions with TRITC-dextran. MM-LDL (100 g/mL) was added to the nonfluorescent solution after 4 perfusions of TRITC-dextran. The buffer used was Krebs-Henseleit solution. All fluorescent and nonfluorescent solutions contained % BSA. All perfusions of the fluorescent and nonfluorescent solutions were of 10-minute duration.
To determine the effects of N-LDL on estradiol interactions with MM-LDL, we performed additional control experiments. First, we measured the rate of dextran accumulation (240Ϯ18.2 ng per cm 2 per h) in the presence of N-LDL (100 g/mL). Then, we added MM-LDL (100 g/mL) to the perfusate and again measured the rate of dextran accumulation with N-LDL in the perfusate (318Ϯ17.3 ng per cm 2 per h; a 32.5% increase in the rate of dextran accumulation). The other carotid artery from the same animal also was used. Initially, we measured the rate of dextran accumulation in the presence of N-LDL and estradiol (at the same concentrations; 324Ϯ3.6 ng per cm 2 per h). Next, MM-LDL was added to the perfusate, and the rate of dextran accumulation was determined in the presence of N-LDL and estradiol (348Ϯ81 ng per cm 2 per h; a 7.4% increase in dextran accumulation). These experiments also showed that MM-LDL increased endothelial layer permeability and that estradiol reduced compromise of the endothelial layer in the presence of N-LDL.
Discussion
Our study showed that estradiol attenuated the accumulation of MM-LDL in the walls of isolated, perfused, rat carotid arteries. Accumulation of MM-LDL and OX-LDL decreased when estradiol was added to the perfusate. Perfusion of MM-LDL increased the accumulation of fluorescently labeled dextran, a marker of increased endothelial layer permeability. The effect of MM-LDL on endothelial layer permeability was nullified by addition of estradiol to the perfusate and indicates that the protective effects of estradiol on the artery wall are mediated, in part, by attenuation of MM-LDLinduced endothelial cell injury.
The interactions of ovarian sex hormones with the artery wall are complex and multifaceted. Physiological concentrations of estrogens have been shown to act directly on the artery wall, 32, 34 to attenuate atherosclerosis, 35 and to reduce morbidity and mortality associated with atherosclerotic cardiovascular disease in postmenopausal women. 36 In comparison, supraphysiolgical concentrations of some estrogens (for example, 17␤-estradiol) can increase LDL accumulation in the artery wall. 32 However, the mechanisms by which estrogens affect the interaction of MM-LDL with the artery wall are incompletely understood and were, therefore, the subject of this article.
To study the interactions of MM-LDL with the artery wall, we used the most direct method possible, by perfusing MM-LDL into the lumen of the artery. This approach is advantageous because it allowed us to directly perfuse a known amount of modified LDL into the artery and analyze the interactions of MM-LDL with the artery wall. This approach enabled us to precisely manipulate the compositions of the perfusate and superfusate solutions and carefully control arterial flow and hydrostatic pressure, hemodynamic parameters known to influence LDL flux into the artery wall. 7, 8, 37 The approach that we have taken enabled us to study the mechanisms of LDL flux into the artery wall and is a bridge between previous in vitro and cell culture experiments and experiments performed on whole-animal preparations. 5, 18, 38 The literature suggests that LDL is primarily modified in the arterial wall because of the large antioxidant capacity of the blood. 39 However, recent data show that modification of LDL can occur in the blood. [13] [14] [15] [16] [17] Furthermore, prolonged LDL circulation times in the blood increase LDL's propensity to oxidation and may lead to LDL modification before it enters the artery wall. 40 Previous work from this laboratory showed that even short exposures to environmental tobacco smoke (4 hours) increased LDL accumulation in the artery wall. This effect appears to be related to modification of LDL by the products of environmental tobacco smoke, a process that may occur in blood. 30 We saw a tendency for MM-LDL to accumulate in the artery wall to a greater extent than did OX-LDL. This could result from a number of possible mechanisms, including induction of substances that increase endothelial layer permeability, such as cytokines (eg, tumor necrosis factor-␣). Also, this interaction could be related to greater oxidative proteolysis of apoB during a longer duration of coppermediated oxidation of LDL. Previous studies showed highavidity binding of constituents of apoB (eg, apoB17) with matrix molecules of the artery wall, such as heparan sulfate proteoglycans. 41 Extensive oxidation of LDL (ie, OX-LDL) may eliminate the exposed portions of apoB on LDL. 27 These studies imply that constituents of apoB are important or necessary for the interaction of LDL with the artery wall.
Researchers from a number of laboratories have investigated the potential antioxidant effects of estrogens. Maziere et al 21 found that 17␤-estradiol, estriol, and estrone inhibited LDL oxidation. Also, pretreatment of endothelial cells and monocyte-like cells with estradiol 24 hours before exposure to OX-LDL prevented cytotoxic effects associated with Ox-LDL. In a similar study, Negre-Salvayre et al 22 reported that estradiol protected cultured bovine endothelial cells from cytotoxic effects of MM-LDL. However, testosterone, progesterone, and cholesterol had no protective effects. Huber et al 42 and Maziere et al 21 reported that estrogens inhibited LDL oxidation and the accumulation of cholesteryl esters in macrophages. Furthermore, in perfused arteries, estradiol was shown to reduce oxidant stress mediated by tumor necrosis Figure 7 . In vivo accumulation of MM-LDL. The right external jugular vein of an ovariectomized rat was isolated and cannulated. DiI-MM-LDL was perfused into the vein to a concentration of 100 g/mL and assuming no clearance of MM-LDL. After a 1-hour perfusion, the right carotid artery was isolated, cannulated, placed in the circulatory loop, and imaged under the fluorescence microscope. An artery treated identically, but not perfused with DiI-MM-LDL, is also shown. Fluorescence intensity increased, indicating that the accumulation of MM-LDL in perfused arteries also was seen in an in vivo model. factor-␣. 43 Therefore, a considerable body of data indicates significant antioxidant effects associated with estrogens.
In our experiments, LDL was already modified when perfused into the arteries. Although estradiol could prevent further modification of LDL in the artery, a primary artery wall effect was suggested. Our studies showed that MM-LDL increased endothelial layer permeability, suggesting endothelial cell injury. Estradiol appeared to prevent this action. We speculate that estradiol partitioned into endothelial cell plasma membranes and stabilized the membranes, possibly by preventing lipid peroxidation or by altering fluidity. 21 The antioxidant properties of estradiol defended endothelial cells from MM-LDL-mediated oxidant stress. Thus, estradiol stabilized the plasma membrane and maintained endothelial layer integrity.
Our studies demonstrated that not only did MM-and OX-LDL accumulate to a greater extent in the artery than did N-LDL but also that their rate of efflux was reduced. This latter effect suggests increased binding of MM-and OX -LDL once they entered the artery wall. Therefore, although increased endothelial layer permeability appeared to be the primary action of MMand OX-LDL on the vessel wall in these studies, increased binding of MM-and OX-LDL to the artery wall also could play a role in total LDL accumulation. However, increased binding, as measured by the rate of efflux, was not prevented by estradiol, as was the increased endothelial layer permeability.
Conclusions
This study and others indicate that an important effect of estradiol treatment is protection of the artery wall from MM-LDL-mediated injury. Mechanistically, estradiol prevented MM-LDL-mediated injury. Although estradiol is likely to have multiple protective effects to prevent atherosclerosis, our study shows that some of the actions of MM-LDL can be ameliorated with estradiol. Because MM-LDL appears to play a critical role in the development of atheroma, hormone replacement therapies may mediate some of LDL's detrimental effects by the antioxidant properties associated with estrogens.
